AXL

AAM to Present at Bank of America's 2023 Global Automotive Summit on April 5

Retrieved on: 
Monday, April 3, 2023
Bank of America, Webcast, AAM, Bank, AXL, NYSE, Satellite navigation device, Broadcasting

DETROIT, April 3, 2023 /PRNewswire/ -- American Axle & Manufacturing Holdings, Inc. (AAM), (NYSE: AXL) will participate in Bank of America's 2023 Global Automotive Summit on April 5.

Key Points: 
  • DETROIT, April 3, 2023 /PRNewswire/ -- American Axle & Manufacturing Holdings, Inc. (AAM), (NYSE: AXL) will participate in Bank of America's 2023 Global Automotive Summit on April 5.
  • AAM is scheduled to present at 9:40 a.m.
  • A live audio webcast will be accessible through the Investor Relations page on AAM's website ( www.aam.com ).
  • A replay of the webcast will be available following the event.

AAM Wins Dorian Award for Bottom Line Improvement

Retrieved on: 
Wednesday, March 22, 2023
Dorian Awards, Problem solving, AAM, Red, AXL, Associate, Engineering, Growth, Bottom line, Rest, NYSE, Award, Management

DETROIT, March 22, 2023 /PRNewswire/ -- American Axle & Manufacturing Holdings, Inc. (AAM), (NYSE: AXL) has received a Dorian Award for Bottom Line Improvement through applying Shainin methods of problem solving.

Key Points: 
  • DETROIT, March 22, 2023 /PRNewswire/ -- American Axle & Manufacturing Holdings, Inc. (AAM), (NYSE: AXL) has received a Dorian Award for Bottom Line Improvement through applying Shainin methods of problem solving.
  • "The Dorian Award celebrates excellence in engineering, and recognizes the contributions of individuals and teams in pushing the boundaries of innovation," said David C. Dauch, AAM Chairman and Chief Executive Officer.
  • The Bottom Line Improvement Dorian Award recognizes companies that have successfully developed a Red X® Program and can demonstrate impactful improvements based on that development.
  • The award is named for Dorian Shainin, inventor of Red X® methodologies and the founder of Shainin, LLC.

Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, March 15, 2023
Progression-free survival, Poster, Research, US, DABT, Sale, PD, Pancreatic cancer, Paclitaxel, Fast Track, Tectonic evolution of the Aravalli Mountains, Serum, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PFS, PDAC, Platinum, AXL, IO, CMC, Executive, Pharming, Patient, FDA, MEC, ASCO, ORR, BLA, Safety, Clinical trial, ODD, PROC, Pharmacokinetics, Food, Therapy, Biologics license application, Nivolumab, Financial toxicity, Pharmaceutical industry, Cryptocurrency

HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported fourth quarter and full year ended December 31, 2022 financial results and provided corporate updates.

Key Points: 
  • HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported fourth quarter and full year ended December 31, 2022 financial results and provided corporate updates.
  • "As we reflect on a productive 2022, Aravive remains committed to driving progress across all aspects of our business," said Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive.
  • If those results are positive, the Company plans on submitting a Biologics License Application (BLA) to FDA by year-end 2023.
  • As of December 31, 2022, cash and cash equivalents were approximately $53.7 million, compared to approximately $27.9 million as of September 30, 2022.

AnHeart Therapeutics Announces Publication of Taletrectinib Global Phase 2 Clinical Trial (TRUST-II) Design in Future Oncology

Retrieved on: 
Thursday, March 9, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, AXL, University of California, Irvine Medical Center, BTD, SD, TKI, Therapy, Future Oncology, Brain, IRC, ROS1, Patient, NSCLC, Progression-free survival, Crizotinib, University, CNS, Breakthrough therapy, Safety, ORR, Trial of the century, Pharmaceutical industry

AnHeart Therapeutics , a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, announced today the publication of clinical trial design of TRUST-II, a global Phase 2 clinical study of taletrectinib in ROS1-positive non-small cell lung cancer and other solid tumors, in the peer-reviewed medical journal, Future Oncology .

Key Points: 
  • AnHeart Therapeutics , a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, announced today the publication of clinical trial design of TRUST-II, a global Phase 2 clinical study of taletrectinib in ROS1-positive non-small cell lung cancer and other solid tumors, in the peer-reviewed medical journal, Future Oncology .
  • The paper, “TRUST-II: A global phase II study of taletrectinib in ROS1-positive non-small cell lung cancer and other solid tumors,” describes the rationale and design of TRUST-II, a global Phase 2 study of taletrectinib in patients with locally advanced/metastatic ROS1+ NSCLC and other ROS1+ solid tumors.
  • Key secondary endpoints include duration of response, progression-free survival, overall survival, and safety.
  • AnHeart Therapeutics (“AnHeart”) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel or next-generation precision oncology therapeutics with high unmet medical needs.

ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, February 28, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MD Anderson Cancer Center, Therapy, Doctor of Philosophy, Medicare Part D, MD, CMO, KAAG1, NYSE, Drug development, Lung cancer, University, Lenalidomide, AXL, S&M, Investment, Patient, Mitsubishi Tanabe Pharma, Medicare (United States), Sarcoma, ASH, Growth, Polatuzumab vedotin, Medicare, CD22, DLBCL, AbbVie, ADC, CFO, Sale, PIN, IHC, Antibody, Roche, G&A, Society, Infrastructure Investment and Jobs Act, Pharmaceutical industry, Video game, Fine chemical, Management, Coal, Reinsurance, EU

ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided business updates.

Key Points: 
  • ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided business updates.
  • “We made good progress across the business in 2022, including laying the crucial groundwork for the ongoing ZYNLONTA launch.
  • The sequential third quarter to fourth quarter slight decline of 7.0% in net sales was due to higher gross-to-net and individual ordering account fluctuations.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss fourth quarter and full year 2022 financial results and provide a company update today at 8:30 a.m. Eastern Time.

Forbes Names AAM Among its 500 Best Large Employers in America for Second Consecutive Year

Retrieved on: 
Thursday, February 16, 2023
Statista, American Axle, Friends, AAM, AXL, NYSE, Family, Automotive industry, Restaurant

DETROIT, Feb. 16, 2023 /PRNewswire/ -- American Axle & Manufacturing (AAM), (NYSE: AXL) is once again on Forbes list of America's Best Large Employers. This prestigious award is presented by Forbes and Statista Inc., the world-leading statistics portal and industry ranking provider. The list spans 25 sectors and can be viewed on the Forbes website.  

Key Points: 
  • DETROIT, Feb. 16, 2023 /PRNewswire/ -- American Axle & Manufacturing (AAM), (NYSE: AXL) is once again on Forbes list of America's Best Large Employers.
  • Forbes and Statista selected its list of America's Best Large Employers 2023 through an independent survey of approximately 45,000 employees working for U.S. companies, each with more than 5,000 employees.
  • This is AAM's fourth selection as one of America's Best Large Employers, having appeared on the list in 2022, 2018 and 2017.
  • The final list ranks the 500 large employers that received the most recommendations.

AAM to Present at Citi's 2023 Global Industrial Tech and Mobility Conference on February 21

Retrieved on: 
Thursday, February 16, 2023
American Axle, Citigroup, AAM, AXL, NYSE, Conference, Webcast, Clothing, Broadcasting, Mobile phone

DETROIT, Feb. 16, 2023 /PRNewswire/ -- American Axle & Manufacturing Holdings, Inc. (AAM), (NYSE: AXL) will participate in the Citi's 2023 Global Industrial Tech and Mobility Conference on February 21.

Key Points: 
  • DETROIT, Feb. 16, 2023 /PRNewswire/ -- American Axle & Manufacturing Holdings, Inc. (AAM), (NYSE: AXL) will participate in the Citi's 2023 Global Industrial Tech and Mobility Conference on February 21.
  • AAM is scheduled to present at 11:20 a.m.
  • A live audio webcast will be accessible through the Investor Relations page on AAM's website ( www.aam.com ).
  • A replay of the webcast will be available following the event.

AAM Recognized by Newsweek as One of America's Most Responsible Companies for 2023

Retrieved on: 
Tuesday, February 14, 2023
American Axle, Corporate governance, Perception, Social responsibility, Environment, AAM, Environmental, social, and corporate governance, AXL, NYSE, ESG, J.D. Power, Annual report, Social, Management, Newsweek

DETROIT, Feb. 14, 2023 /PRNewswire/ -- American Axle & Manufacturing (AAM), (NYSE: AXL) has been recognized by Newsweek as one of America's Most Responsible Companies for 2023. This prestigious award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. The list was announced late last year and can be viewed on Newsweek's website.  

Key Points: 
  • DETROIT, Feb. 14, 2023 /PRNewswire/ -- American Axle & Manufacturing (AAM), (NYSE: AXL) has been recognized by Newsweek as one of America's Most Responsible Companies for 2023.
  • This prestigious award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider.
  • "For three consecutive years AAM has been named by Newsweek as one of America's Most Responsible Companies," said David C. Dauch, AAM Chairman and Chief Executive Officer.
  • The final list recognizes the top 500 most responsible companies in the U.S., spanning 14 industries.

AAM to Announce Fourth Quarter and Full Year 2022 Financial Results on February 17

Retrieved on: 
Friday, February 10, 2023
American Axle, AAM, AXL, NYSE

DETROIT, Feb. 10, 2023 /PRNewswire/ -- American Axle & Manufacturing Holdings, Inc. (AAM), (NYSE: AXL) will hold a conference call to discuss fourth quarter and full year financial results and other related matters at 10:00 a.m.

Key Points: 
  • DETROIT, Feb. 10, 2023 /PRNewswire/ -- American Axle & Manufacturing Holdings, Inc. (AAM), (NYSE: AXL) will hold a conference call to discuss fourth quarter and full year financial results and other related matters at 10:00 a.m.
  • ET on Friday, February 17, 2023.
  • A press release announcing the results will be issued before the market opens on the same day and will be available at www.aam.com .
  • A replay will be available one hour after the call is complete until February 24, 2023.

BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones

Retrieved on: 
Tuesday, January 10, 2023
Liposarcoma, Synovial sarcoma, NSCLC, Nivolumab, UPS, Conditional, FDA, CR, Conference, AXL, Patient, Growth, Therapy, EGFR, Osteosarcoma, ORR, SAN, CAB, PD-1, ALK, Pharmaceutical industry

Company updates and 2023 milestones will be presented in a fireside chat at 41st Annual J.P. Morgan Healthcare Conference, January 10, 2023.

Key Points: 
  • Company updates and 2023 milestones will be presented in a fireside chat at 41st Annual J.P. Morgan Healthcare Conference, January 10, 2023.
  • “BioAtla made significant progress and growth in 2022 and we continue to see encouraging data from both our preclinical and clinical studies.
  • We anticipate 2023 as a promising year ahead with important milestones from multiple clinical programs,” said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc.
    “We are excited with the continued antitumor activity and differentiated safety profile of BA3011, particularly as monotherapy in PD-1-refractory NSCLC patients in our ongoing part 1 of the phase 2 study,” said Scott Smith, President of BioAtla.
  • He continued, “We also remain encouraged with the progress we have made in our Phase 2 part 2 UPS study and BA3071 CAB-CTLA-4 Phase 1 study.